Journal of Neuroimmunology
Volume 217, Issue 1 , Pages 1-7 , 10 December 2009

Small but powerful: Short peptide hormones and their role in autoimmune inflammation

  • F. Lühder

      Affiliations

    • Institute for MS Research, University of Goettingen, Göttingen, Germany
    • ,
  • D.H. Lee

      Affiliations

    • Department of Neurology, St. Josef Hospital, Ruhr-University Bochum, Germany
    • ,
  • R. Gold

      Affiliations

    • Department of Neurology, St. Josef Hospital, Ruhr-University Bochum, Germany
    • ,
  • J. Stegbauer

      Affiliations

    • Department of Nephrology, Heinrich-Heine University, Düsseldorf, Germany
    • ,
  • R.A. Linker

      Affiliations

    • Department of Neurology, St. Josef Hospital, Ruhr-University Bochum, Germany
    • Corresponding Author InformationCorresponding author. Department of Neurology, St. Josef Hospital, Ruhr-University Bochum, D-44791 Bochum, Germany. Tel.: +49 234 509 2411; fax: +49 234 509 2414.

Received 28 July 2009 ,Accepted 19 August 2009.

References 

  1. Asashima T, Iizasa H, Terasaki T, Nakashima E. Rat brain pericyte cell lines expressing beta2-adrenergic receptor, angiotensin II receptor type 1A, klotho, and CXCR4 mRNAs despite having endothelial cell markers. J. Cell. Physiol. 2003;197:69–76
  2. Austinat M, Braeuninger S, Pesquero JB, Brede M, Bader M, Stoll G, et al. Blockade of bradykinin receptor B1 but not bradykinin receptor B2 provides protection from cerebral infarction and brain edema. Stroke. 2009;40:285–293
  3. Bedoui S, Miyake S, Lin YW, Miyamoto K, Oki S, Kawamura N, et al. Neuropeptide Y (NPY) suppresses experimental autoimmune encephalomyelitis: NPY1 receptor-specific inhibition of autoreactive Th1 responses in vivo. J. Immunol. 2003;171:3451–3458
  4. Benigni A, Corna D, Zoja C, Sonzogni A, Latini R, Salio M, et al. Disruption of the Ang II type 1 receptor promotes longevity in mice. J. Clin. Invest. 2009;119:524–530
  5. Benter IF, Yousif MH, Dhaunsi GS, Kaur J, Chappell MC, Diz DI. Angiotensin-(1–7) prevents activation of NADPH oxidase and renal vascular dysfunction in diabetic hypertensive rats. Am. J. Nephrol. 2008;28:25–33
  6. Bettelli E, Carrier YJ, Gao WD, Korn T, Strom TB, Oukka M, et al. Reciprocal developmental pathways for the generation of pathogenic effector T(H)17 and regulatory T cells. Nature. 2006;441:235–238
  7. Brenner BM, Cooper ME, de ZD, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N. Engl. J. Med. 2001;345:861–869
  8. Burson JM, Aguilera G, Gross KW, Sigmund CD. Differential expression of angiotensin receptor 1A and 1B in mouse. Am. J. Physiol. 1994;267:E260–E267
  9. Chen MF, Li YJ, Yang TL, Lou B, Xie XM. Losartan inhibits monocytic adhesion induced by ADMA via downregulation of chemokine receptors in monocytes. Eur. J. Clin. Pharmacol. 2009;65:457–465
  10. Colwell CS, Michel S, Itri J, Rodriguez W, Tam J, Lelievre V, et al. Disrupted circadian rhythms in VIP- and PHI-deficient mice. Am. J. Physiol. 2003;285:R939–R949
  11. Combadiere C, Potteaux S, Rodero M, Simon T, Pezard A, Esposito B, et al. Combined inhibition of CCL2, CX3CR1, and CCR5 abrogates Ly6C(hi) and Ly6C(lo) monocytosis and almost abolishes atherosclerosis in hypercholesterolemic mice. Circulation. 2008;117:1649–1657
  12. Constantinescu CS, Ventura E, Hilliard B, Rostami A. Effects of the angiotensin converting enzyme inhibitor captopril on experimental autoimmune encephalomyelitis. Immunopharmacol. Immunotoxicol. 1995;17:471–491
  13. Crackower MA, Sarao R, Oudit GY, Yagil C, Kozieradzki I, Scanga SE, et al. Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature. 2002;417:822–828
  14. Crowley SD, Vasievich MP, Ruiz P, Gould SK, Parsons KK, Pazmino AK, et al. Glomerular type 1 angiotensin receptors augment kidney injury and inflammation in murine autoimmune nephritis. J. Clin. Invest. 2009;119:943–953
  15. Dai Q, Xu M, Yao M, Sun B. Angiotensin AT1 receptor antagonists exert anti-inflammatory effects in spontaneously hypertensive rats. Br. J. Pharmacol. 2007;152:1042–1048
  16. De CC, Amiri F, Brassard P, Endemann DH, Touyz RM, Schiffrin EL. Reduced vascular remodeling, endothelial dysfunction, and oxidative stress in resistance arteries of angiotensin II-infused macrophage colony-stimulating factor-deficient mice: evidence for a role in inflammation in angiotensin-induced vascular injury. Arterioscler. Thromb. Vasc. Biol. 2005;25:2106–2113
  17. DiBona GF, Kopp UC. Neural control of renal function. Physiol. Rev. 1997;77:75–197
  18. Doerries C, Grote K, Hilfiker-Kleiner D, Luchtefeld M, Schaefer A, Holland SM, et al. Critical role of the NAD(P)H oxidase subunit p47phox for left ventricular remodeling/dysfunction and survival after myocardial infarction. Circ. Res. 2007;100:894–903
  19. Dos Santos AC, Roffe E, Arantes RME, Juliano L, Pesquero JL, Pesquero JB, et al. Kinin B-2 receptor regulates chemokines CCL2 and CCL5 expression and modulates leukocyte recruitment and pathology in experimental autoimmune encephalomyelitis (EAE) in mice. J. Neuroinflammation. 2008;5:49
  20. Dragun D, Muller DN, Brasen JH, Fritsche L, Nieminen-Kelha M, Dechend R, et al. Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N. Engl. J. Med. 2005;352:558–569
  21. Felix D, Schlegel W. Angiotensin receptive neurones in the subfornical organ. Structure–activity relations. Brain Res. 1978;149:107–116
  22. Fernandez-Martin A, Gonzalez-Rey E, Chorny A, Ganea D, Delgado M. Vasoactive intestinal peptide induces regulatory T cells during experimental autoimmune encephalomyelitis. Eur. J. Immunol. 2006;36:318–326
  23. Ferreira AJ, Santos RA. Cardiovascular actions of angiotensin-(1–7). Braz. J. Med. Biol. Res. 2005;38:499–507
  24. Fitzsimons JT. Angiotensin, thirst, and sodium appetite. Physiol. Rev. 1998;78:583–686
  25. Fleegal-DeMotta MA, Doghu S, Banks WA. Angiotensin II modulates BBB permeability via activation of the AT(1) receptor in brain endothelial cells. J. Cereb. Blood Flow Metab. 2009;29:640–647
  26. Germain L, Barabe J, Galeano C. Increased blood-concentration of Des-Arg9-bradykinin in experimental allergic encephalomyelitis. J. Neurol. Sci. 1988;83:211–217
  27. Gold R, Linington C, Lassmann H. Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain. 2006;129:1953–1971
  28. Gonzalez-Rey E, Fernandez-Martin A, Chorny A, Martin J, Pozo D, Ganea D, et al. Therapeutic effect of vasoactive intestinal peptide on experimental autoimmune encephalomyelitis — down-regulation of inflammatory and autoimmune responses. Am. J. Pathol. 2006;168:1179–1188
  29. Gozes I, Divinsky I, Pilzer I, Fridkin M, Brenneman DE, Spier AD. From vasoactive intestinal peptide (VIP) through activity-dependent neuroprotective protein (ADNP) to NAP — a view of neuroprotection and cell division. J. Mol. Neurosci. 2003;20:315–322
  30. Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ. Res. 1994;74:1141–1148
  31. Griendling KK, Lassegue B, Alexander RW. Angiotensin receptors and their therapeutic implications. Annu. Rev. Pharmacol. Toxicol. 1996;36:281–306
  32. Grimm MC, Newman R, Hassim Z, Cuan N, Connor SJ, Le YY, et al. Cutting edge: vasoactive intestinal peptide acts as a potent suppressor of inflammation in vivo by trans-deactivating chemokine receptors. J. Immunol. 2003;171:4990–4994
  33. Grote K, Ortmann M, Salguero G, Doerries C, Landmesser U, Luchtefeld M, et al. Critical role for p47phox in renin–angiotensin system activation and blood pressure regulation. Cardiovasc. Res. 2006;71:596–605
  34. Gurley SB, Coffman TM. Angiotensin-converting enzyme 2 gene targeting studies in mice: mixed messages. Exp. Physiol. 2008;93:538–542
  35. Gurley SB, Allred A, Le TH, Griffiths R, Mao L, Philip N, et al. Altered blood pressure responses and normal cardiac phenotype in ACE2-null mice. J. Clin. Invest. 2006;116:2218–2225
  36. Guyton AC. Blood pressure control — special role of the kidneys and body fluids. Science. 1991;252:1813–1816
  37. Guzik TJ, Hoch NE, Brown KA, McCann LA, Rahman A, Dikalov S, et al. Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction. J. Exp. Med. 2007;204:2449–2460
  38. Hassani H, Lucas G, Rozell B, Ernfors P. Attenuation of acute experimental colitis by preventing NPYY1 receptor signaling. Am. J. Physiol. 2005;288:G550–G556
  39. Henke N, Schmidt-Ullrich R, Dechend R, Park JK, Qadri F, Wellner M, et al. Vascular endothelial cell-specific NF-kappaB suppression attenuates hypertension-induced renal damage. Circ. Res. 2007;101:268–276
  40. Hoch NE, Guzik TJ, Chen W, Deans T, Maalouf SA, Gratze P, et al. Regulation of T-cell function by endogenously produced angiotensin II. Am. J. Physiol. 2009;296:R208–R216
  41. Ishibashi M, Hiasa K, Zhao Q, Inoue S, Ohtani K, Kitamoto S, et al. Critical role of monocyte chemoattractant protein-1 receptor CCR2 on monocytes in hypertension-induced vascular inflammation and remodeling. Circ. Res. 2004;94:1203–1210
  42. Izikson L, Klein RS, Charo IF, Weiner HL, Luster AD. Resistance to experimental autoimmune encephalomyelitis in mice lacking the CC chemokine receptor (CCR)2. J. Exp. Med. 2000;192:1075–1080
  43. Kaschina E, Grzesiak A, Li J, Foryst-Ludwig A, Timm M, Rompe F, et al. Angiotensin II type 2 receptor stimulation: a novel option of therapeutic interference with the renin–angiotensin system in myocardial infarction?. Circulation. 2008;118:2523–2532
  44. Kato H, Ito A, Kawanokuchi J, Jin SJ, Mizuno T, Ojika K, et al. Pituitary adenylate cyclase-activating polypeptide (PACAP) ameliorates experimental autoimmune encephalomyelitis by suppressing the functions of antigen presenting cells. Mult. Scler. 2004;10:651–659
  45. Kawano S, Kubota T, Monden Y, Kawamura N, Tsutsui H, Takeshita A, et al. Blockade of NF-kappaB ameliorates myocardial hypertrophy in response to chronic infusion of angiotensin II. Cardiovasc. Res. 2005;67:689–698
  46. Kvakan H, Kleinewietfeld M, Qadri F, Park JK, Fischer R, Schwarz I, et al. Regulatory T cells ameliorate angiotensin II-induced cardiac damage. Circulation. 2009;119:2904–2912
  47. Lemos VS, Silva DM, Walther T, Alenina N, Bader M, Santos RA. The endothelium-dependent vasodilator effect of the nonpeptide Ang(1–7) mimic AVE 0991 is abolished in the aorta of mas-knockout mice. J. Cardiovasc. Pharmacol. 2005;46:274–279
  48. Linker R, Gold R, Lühder F. Function of neurotrophic factors beyond the nervous system: inflammation and autoimmune demyelination. Crit Rev. Immunol. 2009;29:43–68
  49. Loot AE, Roks AJ, Henning RH, Tio RA, Suurmeijer AJ, Boomsma F, et al. Angiotensin-(1–7) attenuates the development of heart failure after myocardial infarction in rats. Circulation. 2002;105:1548–1550
  50. Lovren F, Pan Y, Quan A, Teoh H, Wang G, Shukla PC, et al. Angiotensin converting enzyme-2 confers endothelial protection and attenuates atherosclerosis. Am. J. Physiol. 2008;295:H1377–H1384
  51. Luft FC, Weinberger MH. Antihypertensive therapy with aliskiren. Kidney Int. 2008;73:679–683
  52. Mapp PI, Kidd BL, Gibson SJ, Terry JM, Revell PA, Ibrahim NBN, et al. Substance-P-related, calcitonin gene-related peptide-flanking and C-flanking peptide of neuropeptide-Y-immunoreactive fibers are present in normal synovium but depleted in patients with rheumatoid-arthritis. Neuroscience. 1990;37:143–153
  53. Marchesi C, Paradis P, Schiffrin EL. Role of the renin–angiotensin system in vascular inflammation. Trends Pharmacol. Sci. 2008;29:367–374
  54. Masaki H, Kurihara T, Yamaki A, Inomata N, Nozawa Y, Mori Y, et al. Cardiac-specific overexpression of angiotensin II AT2 receptor causes attenuated response to AT1 receptor-mediated pressor and chronotropic effects. J. Clin. Invest. 1998;101:527–535
  55. Mehta PK, Griendling KK. Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am. J. Physiol. 2007;292:C82–C97
  56. Mukoyama M, Nakajima M, Horiuchi M, Sasamura H, Pratt RE, Dzau VJ. Expression cloning of type 2 angiotensin II receptor reveals a unique class of seven-transmembrane receptors. J. Biol. Chem. 1993;268:24539–24542
  57. Müller DN, Shagdarsuren E, Park JK, Dechend R, Mervaala E, Hampich F, et al. Immunosuppressive treatment protects against angiotensin II-induced renal damage. Am. J. Pathol. 2002;161:1679–1693
  58. Murphy TJ, Alexander RW, Griendling KK, Runge MS, Bernstein KE. Isolation of a cDNA encoding the vascular type-1 angiotensin II receptor. Nature. 1991;351:233–236
  59. Nahmod KA, Vermeulen ME, Raiden S, Salamone G, Gamberale R, Fernandez-Calotti P, et al. Control of dendritic cell differentiation by angiotensin II. FASEB J. 2003;17:491–493
  60. Nessler S, Stadelmann C, Bittner A, Schlegel K, Gronen F, Brück W, et al. Suppression of autoimmune encephalomyelitis by a neurokinin-1 receptor antagonist — a putative role for substance P in CNS inflammation. J. Neuroimmunol. 2006;179:1–8
  61. Oudit GY, Kassiri Z, Patel MP, Chappell M, Butany J, Backx PH, et al. Angiotensin II-mediated oxidative stress and inflammation mediate the age-dependent cardiomyopathy in ACE2 null mice. Cardiovasc. Res. 2007;75:29–39
  62. Pan HL. Brain angiotensin II and synaptic transmission. Neuroscientist. 2004;10:422–431
  63. Park JK, Fischer R, Dechend R, Shagdarsuren E, Gapeljuk A, Wellner M, et al. p38 mitogen-activated protein kinase inhibition ameliorates angiotensin II-induced target organ damage. Hypertension. 2007;49:481–489
  64. Paul M, Poyan MA, Kreutz R. Physiology of local renin–angiotensin systems. Physiol. Rev. 2006;86:747–803
  65. Pavel J, Tang H, Brimijoin S, Moughamian A, Nishioku T, Benicky J, et al. Expression and transport of angiotensin II AT1 receptors in spinal cord, dorsal root ganglia and sciatic nerve of the rat. Brain Res. 2008;1246:111–122
  66. Peach MJ. Renin–angiotensin system: biochemistry and mechanisms of action. Physiol. Rev. 1977;57:313–370
  67. Petkov V, Mosgoeller W, Ziesche R, Raderer M, Stiebellehner L, Vonbank K, et al. Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension. J. Clin. Invest. 2003;111:1339–1346
  68. Phillips MI, de Oliveira EM. Brain renin angiotensin in disease. J. Mol. Med. 2008;86:715–722
  69. Piper PJ, Said SI, Vane JR. Effects on smooth muscle preparations of unidentified vasoactive peptides from intestine and lung. Nature. 1970;225:1144–&
  70. Platten M, Youssef S, Hur EM, Ho M, Han M, Lanz T, et al. Blocking angiotensin converting enzyme induces potent regulatory T cells and modulates TH1- and TH17-mediated autoimmunity. Proc. Natl. Acad. Sci. U. S. A. 2009;106:14948–14953
  71. Pozo D, Delgado M. The many faces of VIP in neuroimmunology: a cytokine rather a neuropeptide?. FASEB J. 2004;18:1325–1334
  72. Prat A, Biernacki K, Saroli T, Orav JE, Guttmann CRG, Weiner HL, et al. Kinin B-1 receptor expression on multiple sclerosis mononuclear cells — correlation with magnetic resonance imaging T2-weighted lesion volume and clinical disability. Arch. Neurol. 2005;62:795–800
  73. Prod'homme T, Weber MS, Steinman L, Zamvil SS. A neuropeptide in immune-mediated inflammation, Y?. Trends Immunol. 2006;27:164–167
  74. Reichardt HM, Lühder F. Traditional concepts and future avenues of glucocorticoid action in experimental autoimmune encephalomyelitis and multiple sclerosis therapy. Crit. Rev. Immunol. 2009;29:255–273
  75. Said SI, Mutt V. Polypeptide with broad biological activity — isolation from small intestine. Science. 1970;169:1217–1218
  76. Santos RA, Simoes e Silva AC, Maric C, Silva DM, Machado RP, de BI, et al. Angiotensin-(1–7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc. Natl. Acad. Sci. U. S. A. 2003;100:8258–8263
  77. Schieffer B, Luchtefeld M, Braun S, Hilfiker A, Hilfiker-Kleiner D, Drexler H. Role of NAD(P)H oxidase in angiotensin II-induced JAK/STAT signaling and cytokine induction. Circ. Res. 2000;87:1195–1201
  78. Schmeisser A, Soehnlein O, Illmer T, Lorenz HM, Eskafi S, Roerick O, et al. ACE inhibition lowers angiotensin II-induced chemokine expression by reduction of NF-kappaB activity and AT1 receptor expression. Biochem. Biophys. Res. Commun. 2004;325:532–540
  79. Schulze-Topphoff U, Prat A, Prozorovski T, Siffrin V, Paterka M, Herz J, et al. Activation of kinin receptor B1 limits encephalitogenic T lymphocyte recruitment to the central nervous system. Nat. Med. 2009;15:788–793
  80. Shanmugam S, Sandberg K. Ontogeny of angiotensin II receptors. Cell Biol. Int. 1996;20:169–176
  81. Soehnlein O, Schmeisser A, Cicha I, Reiss C, Ulbrich H, Lindbom L, et al. ACE inhibition lowers angiotensin-II-induced monocyte adhesion to HUVEC by reduction of p65 translocation and AT 1 expression. J. Vasc. Res. 2005;42:399–407
  82. Stegbauer J, Vonend O, Oberhauser V, Rump LC. Effects of angiotensin-(1–7) and other bioactive components of the renin–angiotensin system on vascular resistance and noradrenaline release in rat kidney. J. Hypertens. 2003;21:1391–1399
  83. Stegbauer J, Oberhauser V, Vonend O, Rump LC. Angiotensin-(1–7) modulates vascular resistance and sympathetic neurotransmission in kidneys of spontaneously hypertensive rats. Cardiovasc. Res. 2004;61:352–359
  84. Stegbauer J, Lee D, Seubert S, Ellrichmann G, Manzel A, Kvakan H, et al. Role of the renin angiotensin system in autoimmune inflammation of the central nervous system. Proc. Natl. Acad. Sci. U. S. A. 2009;106:14942–14947
  85. Tan YV, Abad C, Lopez R, Dong HM, Liu S, Lee A, et al. Pituitary adenylyl cyclase-activating polypeptide is an intrinsic regulator of Treg abundance and protects against experimental autoimmune encephalomyelitis. Proc. Natl. Acad. Sci U. S. A. 2009;106:2012–2017
  86. Tharaux PL, Coffman TM. Transgenic mice as a tool to study the renin–angiotensin system. Contrib. Nephrol. 2001;72–91
  87. Timmermans PB, Wong PC, Chiu AT, Herblin WF, Smith RD. New perspectives in angiotensin system control. J. Hum. Hypertens. 1993;7(Suppl 2):S19–S31
  88. Towler P, Staker B, Prasad SG, Menon S, Tang J, Parsons T, et al. ACE2 X-ray structures reveal a large hinge-bending motion important for inhibitor binding and catalysis. J. Biol. Chem. 2004;279:17996–18007
  89. Wolf G, Schneider A, Helmchen U, Stahl RA. AT1-receptor antagonists abolish glomerular MCP-1 expression in a model of mesangial proliferative glomerulonephritis. Exp. Nephrol. 1998;6:112–120
  90. Wosik K, Cayrol R, Dodelet-Devillers A, Berthelet F, Bernard M, Moumdjian R, et al. Angiotensin II controls occludin function and is required for blood brain barrier maintenance: relevance to multiple sclerosis. J. Neurosci. 2007;27:9032–9042
  91. Wu K, Zhou T, Sun G, Wang W, Zhang Y, Zhang Y, et al. Valsartan inhibited the accumulation of dendritic cells in rat fibrotic renal tissue. Cell. Mol. Immunol. 2006;3:213–220
  92. Xie QY, Sun M, Yang TL, Sun ZL. Losartan reduces monocyte chemoattractant protein-1 expression in aortic tissues of 2K1C hypertensive rats. Int. J. Cardiol. 2006;110:60–66
  93. Xu HX, Li JJ, Li GS, Wang J, Li NX, Peng J. Decreased infiltration of macrophages and inhibited activation of nuclear factor-kappa B in blood vessels: a possible mechanism for the anti-atherogenic effects of losartan. Acta Cardiol. 2007;62:607–613

PII: S0165-5728(09)00313-0

doi: 10.1016/j.jneuroim.2009.08.008

Journal of Neuroimmunology
Volume 217, Issue 1 , Pages 1-7 , 10 December 2009

Article Tools

* Image Usage & Resolution